Search

Rhythm Pharmaceuticals Inc

Fechado

SetorSaúde

110.98 1.29

Visão Geral

Variação de preço das ações

24h

Atual

Mín

109.4

Máximo

110.45

Indicadores-chave

By Trading Economics

Rendimento

-49M

-105M

Vendas

11M

71M

EPS

-0.73

Margem de lucro

-147.27

Funcionários

414

EBITDA

6.2M

-44M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+29.52% upside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

898M

7.9B

Abertura anterior

109.69

Fecho anterior

110.98

Sentimento de Notícias

By Acuity

26%

74%

70 / 340 Ranking em Healthcare

Rhythm Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de ago. de 2026, 19:36 UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

20 de ago. de 2026, 20:02 UTC

Correlated Moves

Rhythm Pharmaceuticals is lower today, influenced by a significant decline in the Biotechnology sector and high trading volume. The stock has dropped sharply since Wednesday.

13 de ago. de 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 de ago. de 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 de ago. de 2026, 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 de ago. de 2026, 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 de ago. de 2026, 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 de ago. de 2026, 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 de ago. de 2026, 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 de ago. de 2026, 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 de ago. de 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 de jul. de 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 de jul. de 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 de jul. de 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 de jul. de 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 de jul. de 2026, 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 de jul. de 2026, 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 de jul. de 2026, 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 de jul. de 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Comparação entre Pares

Variação de preço

Rhythm Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

29.52% parte superior

Previsão para 12 meses

Média 142.47 USD  29.52%

Máximo 160 USD

Mínimo 105 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Rhythm Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

15

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

70 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat